Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002280
Status:
COMPLETED
Last Update Posted:
2011-08-05
First Post:
1999-11-02
Brief Title:
A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
An Open Label Study Regimen of Videx 23-Dideoxyinosine ddI in Children With Acquired Immunodeficiency Syndrome AIDS Who Have Demonstrated Significant Deterioration or Intolerance to Zidovudine Retrovir
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to make didanosine ddI available to children with AIDS who are clinically deteriorating on zidovudine AZT or intolerant to AZT and cannot enter the Phase II ddI programs due to protocol exclusion or geographic location
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AI454-904 | None | None | None |